BridgeMD
Evaluation of the efficacy of sphenopalatine block in headache in patients with non-traumatic subarachnoid hemorrhage (SAH) after training of neurosurgical intensive care nurses.
EU CTIS ID: 2024-514282-19-00
What this study is testing
Demonstrate a 50% reduction in morphine consumption with sphenopalatine block during the first 72 hours after cerebral arteriography.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- - ≥ 18 years
- - Non-traumatic SAH with or without aneurysm on brain imaging
- - WFNS 1 and 2 scores
- - Patient awake and extubated after radiological procedure
- - Painful patient (EN > 3/10) despite usual level 1 analgesics (Paracetamol + Acupan) for headaches and/or referred spinal pain
- - Affiliated with or benefiting from a social security scheme
You likely can't join if
- - Contraindication to sphenopalatine block (deviated nasal septum, repeated epistaxis, allergy to Lidocaine)
- - Patient unable to assess pain by EN
- - Persons referred to in articles L1121-5 to L1121-8 of the CSP and articles 31 to 35 of Regulation 536/2014
- - Participation in other interventional research with pain as primary end point
- - Patient refusal to participate
- - Arteriography more than 48 hours old
See the full eligibility criteria
- - ≥ 18 years
- - Non-traumatic SAH with or without aneurysm on brain imaging
- - WFNS 1 and 2 scores
- - Patient awake and extubated after radiological procedure
- - Painful patient (EN > 3/10) despite usual level 1 analgesics (Paracetamol + Acupan) for headaches and/or referred spinal pain
- - Affiliated with or benefiting from a social security scheme
- - Contraindication to sphenopalatine block (deviated nasal septum, repeated epistaxis, allergy to Lidocaine)
- - Patient unable to assess pain by EN
- - Persons referred to in articles L1121-5 to L1121-8 of the CSP and articles 31 to 35 of Regulation 536/2014
- - Participation in other interventional research with pain as primary end point
- - Patient refusal to participate
- - Arteriography more than 48 hours old
- - Inaugural headache lasting more than 7 days
- - Presence of an unsecured vascular malformation at high risk of rupture
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.